http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014145694-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014145694-A |
| titleOfInvention | COMBINED TREATMENT OF ANTI-MIF ANTIBODIES AND Glucocorticoids |
| abstract | 1. The combination of anti-MIF antibodies with glucocorticoids for use in the treatment of glucocorticoid-susceptible diseases. The combination of claim 1, wherein the glucocorticoid-susceptible disease responds to glucocorticoid treatment. 3. The combination according to claim 1 or 2 for use in the treatment of inflammation, allergies, cancer or asthma. 4. The combination of claim 1 or 2, wherein the antibody is an anti-oxMIF antibody. The combination according to claim 1 or 2, wherein the anti-MIF antibody is selected from the following group: anti-MIF antibody RAB9, RAB4, RAB0, RAM9, RAM4 and / or RAM0.6. The combination according to claim 1 or 2, wherein the glucocorticoid is selected from the group consisting of glucocorticoid receptor agonists, for example, methylprednisolone, prednisolone, triamcinolone, dexamethasone, parametasone, fluorocortolone, budesonide, fluticasone, flunisolide, cyclonezonazone, coronazonazone, coronazone and anti-inflammatory SEGRA / SEGRM (e.g. Mapracorat (= BOL303242X = ZK245186), compound, RU 24856, RU 24782, RU 40066, ZK 216348) .7. The combination of claim 1 or 2, wherein the anti-MIF antibody is one of RAB9, RAB4, or RAB0, or RAM9, RAM4 or RAMO, preferably a RAM9 antibody, wherein the glucocorticoid is selected from the group in which (methyl) prednisone and dexamethasone for systemic administration, and budesonide for local administration, and the MIF-associated disease is inflammation, in particular nephritis, even more preferably lupus nephritis, glomerulonephritis, IgA or IgM nephropathy, systemic vasculitis (e.g. nodular polyarteritis, Wegen granulomatosis ra and purpura of Schönlein-Genoch), anti-GBM nephritis and / or rapidly progressive glomerulonephritis, (type I, II, III or IV), for example, nephritis with anti-neutrophilic cytoplasmic antibodies (ANCA-nephritis) .8. The combination of claim 1 or 2, wherein the anti-MIF antibody is one |
| priorityDate | 2012-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.